Jason Haas
CIK: 0001883821
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Aug 12, 2026LGND
LIGAND PHARMACEUTICALS INC
Sale(S)Direct7.1K shares at avg. $292.81$2.1M - Aug 12, 2026LGND
LIGAND PHARMACEUTICALS INC
Exercise(M)Direct6.1K shares at avg. $51.56$316K - Jun 12, 2026LGND
LIGAND PHARMACEUTICALS INC
Exercise(M)Direct3K shares at avg. $51.56$155K - Jun 12, 2026LGND
LIGAND PHARMACEUTICALS INC
Exercise(M)Direct1K shares at avg. $51.56$52K - Jun 12, 2026LGND
LIGAND PHARMACEUTICALS INC
Sale(S)Direct3K shares at avg. $255.01$765K - Jun 12, 2026LGND
LIGAND PHARMACEUTICALS INC
Sale(S)Direct3.5K shares at avg. $256.08$886K - Jun 5, 2026LGND
LIGAND PHARMACEUTICALS INC
Award(A)Direct836 shares- - May 8, 2026ODTX
Odyssey Therapeutics, Inc.
Purchase(P)Direct1K shares at avg. $20.00$20K - Jun 6, 2025LGND
LIGAND PHARMACEUTICALS INC
Award(A)Direct1.2K shares- - Nov 18, 2024SYRS
Syros Pharmaceuticals, Inc.
Sale(S)Direct137.8K shares at avg. $0.21$29K - Oct 31, 2024SYRS
Syros Pharmaceuticals, Inc.
Exercise(M)Direct18.9K shares- - Oct 31, 2024SYRS
Syros Pharmaceuticals, Inc.
Tax Payment(F)Direct5.6K shares at avg. $2.09$12K - Sep 12, 2024SYRS
Syros Pharmaceuticals, Inc.
Purchase(P)Direct45.3K shares at avg. $1.68$76K - Sep 11, 2024SYRS
Syros Pharmaceuticals, Inc.
Purchase(P)Direct19.3K shares at avg. $1.58$30K - Sep 10, 2024SYRS
Syros Pharmaceuticals, Inc.
Purchase(P)Direct35.4K shares at avg. $1.55$55K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 12, 2026 |  LGND LIGAND PHARMACEUTICALS INC | Sale(S) | 7,138 | $292.81 | $2,090,062 | Direct |
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | Exercise(M) | 6,138 | $51.56 | $316,475 | Direct |
| Jun 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | Exercise(M) | 3,000 | $51.56 | $154,680 | Direct |
| Jun 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | Exercise(M) | 1,000 | $51.56 | $51,560 | Direct |
| Jun 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | Sale(S) | 3,000 | $255.01 | $765,034 | Direct |
| Jun 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | Sale(S) | 3,461 | $256.08 | $886,286 | Direct |
| Jun 5, 2026 | LGND LIGAND PHARMACEUTICALS INC | Award(A) | 836 | - | $0 | Direct |
| May 8, 2026 |  ODTX Odyssey Therapeutics, Inc. | Purchase(P) | 1,000 | $20.00 | $20,000 | Direct |
| Jun 6, 2025 | LGND LIGAND PHARMACEUTICALS INC | Award(A) | 1,209 | - | - | Direct |
| Nov 18, 2024 |  SYRS Syros Pharmaceuticals, Inc. | Sale(S) | 137,803 | $0.21 | $28,980 | Direct |
| Oct 31, 2024 | SYRS Syros Pharmaceuticals, Inc. | Exercise(M) | 18,875 | - | $0 | Direct |
| Oct 31, 2024 | SYRS Syros Pharmaceuticals, Inc. | Tax Payment(F) | 5,624 | $2.09 | $11,754 | Direct |
| Sep 12, 2024 | SYRS Syros Pharmaceuticals, Inc. | Purchase(P) | 45,344 | $1.68 | $76,006 | Direct |
| Sep 11, 2024 | SYRS Syros Pharmaceuticals, Inc. | Purchase(P) | 19,293 | $1.58 | $30,446 | Direct |
| Sep 10, 2024 | SYRS Syros Pharmaceuticals, Inc. | Purchase(P) | 35,363 | $1.55 | $54,788 | Direct |
1-15 of 15 transactions
About Haas Jason
Haas Jason (SEC CIK 0001883821) files insider reports with the SEC as Director of LIGAND PHARMACEUTICALS INC (LGND), Chief Financial Officer of Odyssey Therapeutics, Inc. (ODTX) and Chief Financial Officer of Syros Pharmaceuticals, Inc. (SYRS).
Signal8 holds 9 ownership filings by Haas Jason (1 Form 3, 8 Form 4), filed between Sep 12, 2024 and Aug 14, 2026. Those filings report 15 transactions, from Sep 10, 2024 to Aug 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Haas Jason's filings is in JUPITER, FL.
Recent filings by Haas Jason
- Aug 12, 2026: Open-market sale of LGND shares (Form 4, code S).
- Aug 12, 2026: Option exercise of LGND shares (Form 4, code M).
- Jun 12, 2026: Option exercises of LGND shares (2 lines, Form 4, code M).
- Jun 12, 2026: Open-market sales of LGND shares (2 lines, Form 4, code S).
- Jun 5, 2026: Grant or award of LGND shares (Form 4, code A).
Other insiders filing for LIGAND PHARMACEUTICALS INC (LGND)
- Aryeh Jason, Director
- Reardon Andrew, CLO & Secretary
- Zimmermann Martine, Director
- Espinoza Octavio, Chief Financial Officer
- Davis Todd C, Chief Executive Officer
- Sabba Stephen L, Director